Skip to main content

Insulin Pump Market Size to Surpass USD 15.51 Billion by 2030, exhibiting a CAGR of 16.2%

As per the report by Fortune Business Insights, the global Insulin Pump Market size is projected to reach USD 15.51 billion in 2030, at a CAGR of 16.2% during the forecast period, 2023-2030

Pune, India, May 23, 2023 (GLOBE NEWSWIRE) — According to Fortune Business Insights, global Insulin Pump Market size was valued at USD 4.60 billion in 2022 and is projected to grow from USD 5.23 billion in 2023 to USD 15.51 billion by 2030, exhibiting a CAGR of 16.2% during the forecast period. Insulin pumps are compact, computerized devices that supply pre-determined doses of insulin to a diabetic person. Since the prevalence of type 1 diabetes is increasing at a worrying rate across the world, the demand for these devices has risen tremendously, thereby boosting the global insulin pump market growth. Fortune Business Insights presents this information in its report titled “Insulin Pump Market Forecast, 2023-2030”.


Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/insulin-pump-market-102735


Key Industry Development:

March 2022 – Ypsomed AG announced its partnership with Abbott and CamDiab to speed up the creation of an automated insulin delivery device for diabetic patients. The device is designed to combine CamDiab’s CamAPS FX algorithm, Abbott’s FreeStyle Libre 3 sensor, and Ypsomed’s mylife YpsoPump to automate the process of delivering insulin in a patient based on real-time glucose data.

Key Takeaways:

  • The market for insulin pumps has grown in recent years to cater to the rising demand for portable insulin delivery devices among the diabetic population.
  • The segment is expected to grow during the forecast period as the penetration of insulin delivery devices is increasing globally.
  • The insulin pump market in North America was valued at USD 2.66 billion in 2022.

Discover the Leading Players Featured in the Report:

“Companies leading the Insulin Pump Market are Medtronic (Ireland), Tandem Diabetes Care, Inc. (U.S.), Ypsomed AG (Switzerland), Insulet Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), CeQur Simplicity (Switzerland), Microtec Medical Ltd (U.K.), ViCentra B.V. (Netherlands), SOOIL Developments Co., Ltd (Korea), EOFLOW CO., LTD. (Korea)

Report Scope & Segmentation:

Report CoverageDetails
Forecast Period2023 to 2030
Forecast Period 2023 to 2030 CAGR16.2%
2030 Value ProjectionUSD 15.51 Billion
Base Year2022
Market Size in 2022USD 4.60 Billion
Historical Data2019 to 2021
No. of Pages181
Segments coveredProduct Type, Disease Indication, Distribution Channel, and Region


Browse Complete Report Details: https://www.fortunebusinessinsights.com/insulin-pump-market-102735


Drivers and Restraints:

Growing Incidence of Diabetes to Accelerate Market Growth

The number of people suffering from diabetes is rising across the globe every year. Many factors, such as obesity, unhealthy dietary habits, and sedentary lifestyle, can increase an individual’s risk of being diagnosed with this ailment. The rising geriatric population is another factor that is contributing to the growing pool of patients suffering from diabetes. The percentage of people suffering from type 1 diabetes is increasing each year, which will further boost the demand for insulin pumps.

However, high costs associated with these pumps is expected to reduce their sales, thereby limiting the market growth.

Segments:

Pumps to Witness Robust Demand for their Beneficial Characteristics

On the basis of product type, the market is segmented into pumps and consumables.

The pumps segment captured a sizable market share due to their growing usage among diabetic patients in developing countries. These products provide a wide range of benefits over Multiple Daily Injections (MDIs), Continuous Glucose Monitors, and other devices.

Growing Prevalence of Type 1 Diabetes to Boost Product Adoption

Based on disease indication, the market is segmented into type 1 diabetes and type 2 diabetes. The type 1 diabetes segment held a dominant position in the market in 2021 due to the growing incidence of this ailment. Since patients diagnosed with type 1 diabetes are heavily dependent on insulin, the demand for insulin pumps will rise.

Retail & Online Pharmacies to Notice Steady Rise in Product Sales Due to their Convenience

In terms of distribution channel, the market is segmented into online & retail pharmacy and hospital pharmacy. The retail & online pharmacy segment captured a significant market share due to the rising availability of a variety of diabetes management devices and solutions in retail and online medical stores across developing and developed countries.

Market Segmentation:

By Product Type

  • Pumps
  • Tethered Pumps
  • Patch Pumps
  • Others
  • Consumables 

By Disease Indication

  • Type 1 Diabetes
  • Type 2 Diabetes

By Distribution Channel

  • Hospital Pharmacy
  • Retail & Online Pharmacy

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


Quick Buy – Insulin Pump Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102735


Regional Insights:

North America to Dominate Due to Rollout of Favorable Reimbursement Policies

North America dominated this market as the government started introducing favorable reimbursement policies in the U.S. to promote the adoption of insulin delivery devices. For example, Medicare Parts A & B offer coverage for tubeless and tubed pumps, respectively, and require a patient to only bear 20% of the total cost of the pump. The region also has a notable presence of reputed medical device manufacturing companies, such as Insulet Corporation and Tandem Diabetes Care, thereby boosting the market growth.

Competitive Landscape:

Medtronic to Capture Major Market Share Due to its Strong Product Portfolio

A few leading companies have captured a large share of the market, and industry leader Medtronic has held a dominant position in the market. This is attributed to the fact that the company has a strong portfolio of innovative pumps and consumables to manage diabetes effectively.


FAQs

What is the market of insulin pumps?

Insulin pumps market size was USD 4.60 billion in 2022. It is expected to reach USD 15.51 billion by 2030.

How fast is the insulin pumps market growing?

The insulin pumps market will exhibit a CAGR of 16.2% during the forecast period, 2023-2030.


Related Reports:

Blood Glucose Monitoring System Market Size, Share, Revenue Forecast and Opportunities

Diabetes Devices Market Overview, Industry Share and Forecast

Infusion Pump Market Size, Share, Opportunities & Analysis


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.